A changing time: the International Society for Cellular Therapy embraces its industry members
Robert Deans(Rubius Therapeutics (United States)), Richard T. Maziarz(Oregon Health & Science University), Ed Field(Codagenix (United States)), René Lardenoije(Pharmac), Scott R. Burger(University of Minnesota), John E.J. Rasko(Macau University of Science and Technology), Timothy E. Allsopp(Pfizer (United States)), Tracey Lodie, Tara Clark(Miltenyi Biotec (Germany)), Kurt C. Gunter(Medica (United States)), Richard Neubiser(CellGenix (Germany)), Jon A. Rowley(University of Michigan–Ann Arbor), Charles S. Cox(The University of Texas Health Science Center), Melissa Carpenter(Unknown), Mark Bonyhadi(Thermo Fisher Scientific (Norway)), Dawn Driscoll(490 BioTech (United States)), Chris Mason(Oak Ridge National Laboratory), Ralf Huss(University Hospital Augsburg)
Cited by 1
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441